A Prospective Post-Marketing Observational Safety Study of Verzenios® (Abemaciclib) Among Breast Cancer Patients in China

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT05267327

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:38:46.300918+00:00

Published At

2022-03-04T00:00:00+00:00

Record Updated At

2022-03-04

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["The Incidence of AEs and SAEs Receiving Verzenios\u00ae Over a Period of Approximately 24 Weeks"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2022-03-04"

protocolSection.identificationModule.nctId

"NCT05267327"

protocolSection.identificationModule.officialTitle

"A Prospective Post-Marketing Observational Safety Study of Verzenios\u00ae (Abemaciclib) Among Breast Cancer Patients in China"

protocolSection.statusModule.overallStatus

"NOT_YET_RECRUITING"

protocolSection.designModule.phases

[]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• The Incidence of AEs and SAEs Receiving Verzenios® Over a Period of Approximately 24 Weeks (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.